
Associated Press - August 6, 2009
One agreement, with Mylan Inc., lowers the annual price of four antiretroviral drugs that are used as a second line of treatment when patients develop a resistance to the first drugs they are treated with. The other agreement, with Pfizer Inc., reduces the cost of a medication that can be used in conjunction with the drugs in patients who have tuberculosis.
The agreements would help drugs "reach hundreds of thousands more people and save hundreds of thousands of more lives. This is a very big deal," Clinton said Thursday in announcing the deal.
Clinton said Mylan, through its subsidiary Matrix Laboratories Limited, would bring the annual cost of the antiretroviral drugs atazanavir, ritonavir, tenofovir and lamivudine down to under $500.
Starting in 2010, the pills will be packaged together and sold as something patients can take once a day, for an annual price of $425. The Clinton Foundation said that price is 28 percent lower than the current lowest-priced alternative.
Pfizer will sell the tuberculosis drug rifabutin at $1 per dose, a 60 percent price decrease, or $90 for a full, six-month treatment. Clinton said tuberculosis is the leading cause of death among HIV patients, but interactions between standard tuberculosis treatments and second-line drugs can hamper treatment. Pfizer's rifabutin does not have the same interactions with the second-line drugs.
Clinton said the drugs would be even more important in coming years, as more people become resistant to the first line of treatment drugs.
Since starting its HIV/AIDS Initiative in 2002, the Clinton Foundation has worked with 25 countries in Africa, the Caribbean and Asia to set up AIDS treatment and prevention programs.
The foundation also provides access to lower-priced AIDS drugs in 70 countries. Clinton said more than 2 million people are now receiving AIDS drugs purchased under these pricing agreements.
090806
AP090806
Copyright © 2009 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .